Clinical Trial Update: Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age. [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing the safety and reactogenicity of GSK's dTpa vaccine Boostrix when given to children aged 6-8 years; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Tetanus

Drugs mentioned

• Boostrix (Diphtheria, Tetanus, and Acellular Pertussis Vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Tetanus, Diphtheria | Phase 3 | Status: COMPLETED